卡多尼单抗对复发性宫颈癌有效且安全

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-10-25 DOI:10.1038/s41571-024-00962-3

Diana Romero

{"title":"卡多尼单抗对复发性宫颈癌有效且安全","authors":"Diana Romero","doi":"10.1038/s41571-024-00962-3","DOIUrl":null,"url":null,"abstract":"The standard-of-care (SOC) first-line treatment for patients with recurrent or metastatic cervical cancer is chemotherapy with a platinum-based agent and paclitaxel, with or without bevacizumab, and with addition of an anti-PD-1 antibody in those with a PD-L1 combined positive score (CPS) ≥1. Now, data from the phase III COMPASSION-16 trial show that addition of the PD-1 × CTLA4 bispecific antibody cadonilimab to chemotherapy plus bevacizumab improves outcomes in this setting.In this trial, conducted in China, 445 women were randomly allocated (1:1) to receive first-line chemotherapy with or without bevacizumab plus either cadonilimab or placebo. Progression-free survival (PFS) and overall survival (OS) were the co-primary end points.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"31 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cadonilimab is effective and safe in recurrent cervical cancer\",\"authors\":\"Diana Romero\",\"doi\":\"10.1038/s41571-024-00962-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The standard-of-care (SOC) first-line treatment for patients with recurrent or metastatic cervical cancer is chemotherapy with a platinum-based agent and paclitaxel, with or without bevacizumab, and with addition of an anti-PD-1 antibody in those with a PD-L1 combined positive score (CPS) ≥1. Now, data from the phase III COMPASSION-16 trial show that addition of the PD-1 × CTLA4 bispecific antibody cadonilimab to chemotherapy plus bevacizumab improves outcomes in this setting.In this trial, conducted in China, 445 women were randomly allocated (1:1) to receive first-line chemotherapy with or without bevacizumab plus either cadonilimab or placebo. Progression-free survival (PFS) and overall survival (OS) were the co-primary end points.\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2024-10-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-024-00962-3\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-024-00962-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

复发性或转移性宫颈癌患者的一线治疗标准（SOC）是使用铂类药物和紫杉醇进行化疗，同时使用或不使用贝伐珠单抗，并在PD-L1联合阳性评分（CPS）≥1的患者中添加抗PD-1抗体。现在，来自III期COMPASSION-16试验的数据显示，在化疗加贝伐珠单抗的基础上加用PD-1 × CTLA4双特异性抗体卡多尼单抗可改善这种情况下的疗效。在这项在中国进行的试验中，445名女性患者被随机分配（1:1）接受一线化疗加或不加贝伐珠单抗加卡多尼单抗或安慰剂。无进展生存期（PFS）和总生存期（OS）是共同主要终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cadonilimab is effective and safe in recurrent cervical cancer

The standard-of-care (SOC) first-line treatment for patients with recurrent or metastatic cervical cancer is chemotherapy with a platinum-based agent and paclitaxel, with or without bevacizumab, and with addition of an anti-PD-1 antibody in those with a PD-L1 combined positive score (CPS) ≥1. Now, data from the phase III COMPASSION-16 trial show that addition of the PD-1 × CTLA4 bispecific antibody cadonilimab to chemotherapy plus bevacizumab improves outcomes in this setting.

In this trial, conducted in China, 445 women were randomly allocated (1:1) to receive first-line chemotherapy with or without bevacizumab plus either cadonilimab or placebo. Progression-free survival (PFS) and overall survival (OS) were the co-primary end points.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.